Safety Population Clause Samples
The Safety Population clause defines the group of participants in a clinical trial who are included in the analysis of safety data. Typically, this population consists of all subjects who have received at least one dose of the investigational product, regardless of whether they completed the study as planned. By clearly specifying which participants' data will be analyzed for safety outcomes, this clause ensures consistency in reporting adverse events and helps maintain the integrity and reliability of the trial's safety assessments.
Safety Population. The Safety Population is comprised of all patients who receive one or more doses of study medication. The Modified ITT Population includes all patients with Pretreatment and End-of-Treatment evaluable radiologic assessments.
Safety Population. The Safety Population is comprised of all subjects who qualify on the basis of Study BA058-05-003 and provide informed consent to enroll in this Extension Study.
Safety Population. The Safety Population will include all patients who received at least one dose of study drug. This population will be used to summarize the safety data. Patients will be analyzed according to their treatment received; if an error in issuing IP occurs and a patient receives a mix of treatments, they will be analyzed under the treatment arm with the most IP issued to the patient.
Safety Population. The Safety population will include all subjects who receive the injection of i.vt. RBM-007. It will be the study population for safety analyses performed with subjects as treated.
Safety Population. The safety population will include all subjects who receive at least one dose of IP. This population will be used for safety analyses. If the randomized treatment arm differs from the actual treatment for a given subject, that subject will be analyzed according to the actual treatment arm.